Chemoradiation in nasopharyngeal carcinoma: a 6-year experience in Tehran cancer institute
Acta Medica Iranica. 2011; 49 (1): 49-53
in English
| IMEMR
| ID: emr-124527
ABSTRACT
To determine the addition of value of neoadjuvant, concurrent and adjuvant chemotherapy to radiation in the treatment of nasopharyngeal carcinoma with regard to the overall survival [OS] and disease free survival [DPS] within a six year period in Tehran cancer institute. Files of all patients with nasopharyngeal carcinoma treated by radiotherapy with or without concurrent chemotherapy in a curative setting in Tehran cancer institute during the period of 1999-2005 were retrospectively reviewed. A total of 103 patients with nasopharyngeal carcinoma had been treated during the study period with radiotherapy or chemoradiotherapy in our institute. There were 29 [28.2%] females and 74 [71.8%] males. The median age at the time of radiotherapy was 47 years old [range 9-75 years]. The patients were followed 2 to 76 months with a median follow-up of 14 months. Time of first recurrence after treatment was 3-44 months with a median of 10 months. Survival in 2 groups of patients treated with radiotherapy alone or chemoradiation did not have a significant difference [P>0.1]. Two-year survival in patients treated with or without adjuvant chemotherapy and had local recurrence after treatment did not have significant difference [P>0.1]. Two-year survival in patients with or without local recurrence after treatment did not have significant difference [P>0.1]. A beneficial effect or a survival benefit of adjuvant/neoadjuvant chemotherapy and concurrent chemoradiation was not observed in Iranian patients
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Radiotherapy
/
Survival
/
Retrospective Studies
/
Chemotherapy, Adjuvant
/
Disease-Free Survival
/
Neoadjuvant Therapy
/
Chemoradiotherapy
/
Antineoplastic Agents
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
Acta Med. Iran.
Year:
2011
Similar
MEDLINE
...
LILACS
LIS